MXPA04002338A - Derivados de carbazol y su uso como antagonistas receptores del npy5. - Google Patents

Derivados de carbazol y su uso como antagonistas receptores del npy5.

Info

Publication number
MXPA04002338A
MXPA04002338A MXPA04002338A MXPA04002338A MXPA04002338A MX PA04002338 A MXPA04002338 A MX PA04002338A MX PA04002338 A MXPA04002338 A MX PA04002338A MX PA04002338 A MXPA04002338 A MX PA04002338A MX PA04002338 A MXPA04002338 A MX PA04002338A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
carbazole derivatives
npy5 receptor
formula
npy5
Prior art date
Application number
MXPA04002338A
Other languages
English (en)
Inventor
Michael Block Howard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04002338A publication Critical patent/MXPA04002338A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Se describe el uso de un compuesto de la formula (I) en la obtencion de un medicamento para el tratamiento de un animal de sangre caliente de los desordenes regulados por el receptor del neuropeptido Y5 (I), en donde R1, R2, R3 y X1- X6 son como se definen en la presente o una sal aceptable farmaceuticamente, pro-farmaco o solvato del mismo. Las composiciones farmaceuticas, los metodos y los procedimientos para la preparacion de los compuestos de la formula (I) son tambien descritos.
MXPA04002338A 2001-09-11 2002-09-09 Derivados de carbazol y su uso como antagonistas receptores del npy5. MXPA04002338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121941.9A GB0121941D0 (en) 2001-09-11 2001-09-11 Chemical compounds
PCT/GB2002/004109 WO2003022849A1 (en) 2001-09-11 2002-09-09 Carbazole derivatives and their use as npy5 receptor antagonists

Publications (1)

Publication Number Publication Date
MXPA04002338A true MXPA04002338A (es) 2004-06-29

Family

ID=9921890

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002338A MXPA04002338A (es) 2001-09-11 2002-09-09 Derivados de carbazol y su uso como antagonistas receptores del npy5.

Country Status (14)

Country Link
US (1) US7408064B2 (es)
EP (1) EP1427729A1 (es)
JP (1) JP2005516892A (es)
KR (1) KR20040036939A (es)
CN (1) CN1653067A (es)
BR (1) BR0212484A (es)
CA (1) CA2459973A1 (es)
GB (1) GB0121941D0 (es)
IL (1) IL160771A0 (es)
MX (1) MXPA04002338A (es)
NO (1) NO20041008L (es)
NZ (1) NZ531678A (es)
WO (1) WO2003022849A1 (es)
ZA (1) ZA200401956B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN100503607C (zh) * 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
US7732447B2 (en) 2006-06-22 2010-06-08 Cephalon, Inc. Fused [d]pyridazin-7-ones
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CA2725754C (en) * 2008-06-11 2017-05-23 Hazel Joan Dyke Diazacarbazoles and methods of use
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA025380B1 (ru) 2011-02-25 2016-12-30 Мерк Шарп Энд Домэ Корп. Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111850A (en) * 1977-02-16 1978-09-05 Amp Incorporated Organic photoconductors and methods
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
JPS6079348A (ja) 1983-10-06 1985-05-07 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US5234942A (en) * 1984-10-19 1993-08-10 Ici Americas Inc. Heterocyclic amides and leucotriene antagonistic use thereof
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
EP0304223A3 (en) * 1987-08-17 1990-10-24 Merck & Co. Inc. Beta-carbolines as cholecy-stokinin and gastrin antagonist
US5223509A (en) * 1987-08-17 1993-06-29 Merck & Co., Inc. β-carbolines as cholecystokinin and gastrin antagonists
EP0342433A3 (en) 1988-05-19 1991-06-19 American Cyanamid Company Substituted dibenzothiaphenes
CA1285827C (en) * 1988-06-03 1991-07-09 Richard Barr Life step stabilizer
AU626980B2 (en) 1989-02-02 1992-08-13 Astellas Pharma Inc. Tetrahydrobenzimidazole derivatives
US5254135A (en) * 1989-10-20 1993-10-19 L'oreal Methods for dyeing keratinous fibres with aminoindoles, compositions and devices for use
CA2032427A1 (en) * 1989-12-18 1991-06-19 Mark G. Bock Benzodiazepines analogs
AU642041B2 (en) 1990-09-13 1993-10-07 Beecham Group Plc Indole ureas as 5 HT receptor antagonist
ES2114569T3 (es) 1991-10-16 1998-06-01 Richardson Vicks Inc Sistema mejorado de penetracion en la piel para la administracion topica mejorada de farmacos.
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
GB9203637D0 (en) 1992-02-19 1992-04-08 Smithkline Beecham Plc Novel treatment
WO1993018026A1 (en) 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
NZ290936A (en) 1994-09-30 1998-01-26 Pfizer 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
WO1997020821A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl derivatives
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
EP0882707B1 (en) * 1996-01-10 2003-10-08 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
AU734710B2 (en) 1996-07-08 2001-06-21 Kyowa Hakko Kirin Co., Ltd. Calcium receptor active compounds
JP3679207B2 (ja) 1996-09-12 2005-08-03 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
WO1998025907A1 (fr) 1996-12-12 1998-06-18 Banyu Pharmaceutical Co., Ltd. Derives de pyrazole
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
EP0927166A1 (en) 1997-02-14 1999-07-07 Bayer Corporation Amides as npy5 receptor antagonists
US6534496B1 (en) 1997-04-17 2003-03-18 Takeda Chemical Industries, Inc. Thermogenic composition and benzazepine thermogenics
FR2763942B1 (fr) 1997-06-02 2002-09-13 Asepta Sa Lab Nouveau procede de preparation de n-acylaminoacides
EP0997458A4 (en) 1997-07-03 2003-03-05 Asahi Chemical Ind NOVEL TRICYCLIC COMPOUNDS HAVING SATUROUS CORES AND MEDICINAL COMPOSITIONS CONTAINING THEM
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
JPH11130817A (ja) 1997-08-28 1999-05-18 Junji Kido ビニル系重合体及びそれを用いたエレクトロルミネッセンス素子
DE19753522A1 (de) 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JPH11174077A (ja) 1997-12-09 1999-07-02 Hokuriku Electric Ind Co Ltd 加速度検出装置
MXPA00006233A (es) 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
ATE297383T1 (de) 1997-12-22 2005-06-15 Bayer Pharmaceuticals Corp Hemmung der p38 kinase unter verwendung von symmetrischen und asymmetrischen diphenylharnstoffen
JP2002507611A (ja) 1998-03-25 2002-03-12 ブリストル−マイヤーズ スクイブ カンパニー イミダゾロン食欲抑制薬：ｉｉ．フェニル誘導体
JP2002507598A (ja) 1998-03-26 2002-03-12 スージェン・インコーポレーテッド チロシン蛋白質キナーゼを調節するためのヘテロ環式化合物のファミリー
US6221875B1 (en) 1998-04-02 2001-04-24 Neurogen Corporation Substituted 9H-pyridino [2,3-B]indole and 9H-pyrimidino [4,5-B]indole derivatives: selective neuropeptide Y receptor ligands
AU3464599A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted 9h-pyridino(2,3-b)indole and 9h-pyrimidino(4,5-b)indole derivatives
AUPP285898A0 (en) 1998-04-07 1998-04-30 Fujisawa Pharmaceutical Co., Ltd. Amido derivatives
JP2004503462A (ja) 1998-04-29 2004-02-05 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 肥満症及び他の障害の処置において有用な神経ペプチドｙｙ５レセプターのためのリガンドとしてのｎ−置換アミノテトラリン
EP1086078B1 (en) 1998-06-08 2003-02-05 Schering Corporation Neuropeptide y5 receptor antagonists
IL141063A (en) 1998-08-07 2005-06-19 Applied Research Systems Derivatives of pyrrolidine-2-carboxylic acid and piperidine-2-carboxylic acids and pharmaceutical compositions comprising said derivatives for treating infertility
JP2002526521A (ja) 1998-10-07 2002-08-20 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経ペプチドｙのｙ５受容体のリガンドとしてのｎ−アラルキルアミノテトラリン
JP2002527507A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
AU3840000A (en) 1999-04-20 2000-11-02 Meiji Seika Kaisha Ltd. Tricyclic compounds
DE60023128T2 (de) 1999-05-12 2006-07-06 Ortho-Mcneil Pharmaceutical, Inc. Pyrazolcarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
GB0011013D0 (en) 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
WO2001090120A2 (en) 2000-05-19 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the evx1 gene
MXPA03005648A (es) * 2000-12-22 2003-10-06 Astrazeneca Ab Derivados de carbazol y su uso, como ligandos de receptor del neuropeptido y5.
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
CA2459973A1 (en) 2003-03-20
IL160771A0 (en) 2004-08-31
NO20041008L (no) 2004-03-10
CN1653067A (zh) 2005-08-10
US7408064B2 (en) 2008-08-05
BR0212484A (pt) 2004-08-24
ZA200401956B (en) 2005-04-15
US20050065157A1 (en) 2005-03-24
GB0121941D0 (en) 2001-10-31
JP2005516892A (ja) 2005-06-09
NZ531678A (en) 2005-09-30
EP1427729A1 (en) 2004-06-16
KR20040036939A (ko) 2004-05-03
WO2003022849A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
BRPI0519398A2 (pt) compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
MY130803A (en) New quinuclidine amide derivatives
TW200621762A (en) Novel compounds
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
MY138086A (en) Novel urea derivative as vanilloid receptor-1 antagonist
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
MY138352A (en) Benzothiazole derivatives
JO2371B1 (en) 4-phenyl-pyridine derivatives
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
WO2003048164A3 (en) Adenosine a2a receptor antagonists
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
SE0104341D0 (sv) New use
TW200606164A (en) New compounds
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
GB0112348D0 (en) Compounds
WO2005118579A3 (en) Thiazole derivatives as chemokine receptor antagonists
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
ATE386725T1 (de) Heterocyclylverbindungen
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
GB0109122D0 (en) Novel compounds
TW200800984A (en) New compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal